29th Mar 2010 15:45
|
For immediate release |
29 March 2010 |
ABCAM PLC
("Abcam" or "the Company")
PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of the PDMRs:
|
Name |
Partnership Shares purchased on 26 March 2010 at 1215 pence per share |
Matching Shares awarded on 26 March 2010 at 1215 pence per share |
Subsequent Beneficial Interest in the Company |
Subsequent percentage holding of issued share capital |
|
Mark Bushfield |
11 |
11 |
73 |
0.0002% |
|
Philippe Cotrel |
10 |
10 |
343 |
0.0010% |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded. No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their release.
The Company has also been notified that on 29 March 2010, Jane Cooke, a PDMR of the Company, exercised share options over 5654 ordinary shares of 1 pence each in the Company at an exercise price of 280p per share. Following this transaction, Mrs Cooke's total beneficial interest in the Company is 9551 ordinary shares representing approximately 0.03 per cent. of the current issued share capital of the Company.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
|
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Stasa Filiplic |
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
Related Shares:
ABC.L